Milatuzumab Stocks List

Recent Signals

Date Stock Signal Type
2019-08-16 IMMU Crossed Above 20 DMA Bullish
2019-08-16 IMMU Non-ADX 1,2,3,4 Bullish Bullish Swing Setup
2019-08-16 IMMU 180 Bullish Setup Bullish Swing Setup
2019-08-16 STRO Spinning Top Other
2019-08-16 STRO New Downtrend Bearish
2019-08-16 STRO Lower Bollinger Band Walk Weakness

Milatuzumab (or hLL1) is an anti-CD74 humanized monoclonal antibody for the treatment of multiple myeloma non-Hodgkin’s lymphoma and chronic lymphocytic leukemia.The drug is the first anti-CD74 antibody that has entered into human testing and is currently being studied for the treatment of multiple myeloma. Milatuzumab has received orphan drug designation from the Food and Drug Administration in the United States for the treatment of multiple myeloma and chronic lymphocytic leukemia.
Milatuzumab was developed by Immunomedics, Inc, (Morris Plains NJ USA).

More about Milatuzumab